Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8D0C

Human SARM1 TIR domain bound to NB-3-ADPR

8D0C の概要
エントリーDOI10.2210/pdb8d0c/pdb
関連するPDBエントリー8D0D 8D0E 8D0F 8D0G 8D0H 8D0I 8D0J 8D0M
分子名称NAD(+) hydrolase SARM1, [[(2~{R},3~{S},4~{R},5~{R})-5-(6-aminopurin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{R},3~{S},4~{R},5~{R})-5-[4-[(1~{S})-1-[methyl-[2,2,2-tris(fluoranyl)ethylcarbamoyl]amino]ethyl]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methyl hydrogen phosphate (3 entities in total)
機能のキーワードnad, hydrolase, axon degeneration, neuroscience, hydrolase-inhibitor complex, hydrolase/inhibitor
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計34018.25
構造登録者
Bratkowski, M.A.,Mathur, P. (登録日: 2022-05-26, 公開日: 2022-09-21, 最終更新日: 2023-10-25)
主引用文献Bratkowski, M.,Burdett, T.C.,Danao, J.,Wang, X.,Mathur, P.,Gu, W.,Beckstead, J.A.,Talreja, S.,Yang, Y.S.,Danko, G.,Park, J.H.,Walton, M.,Brown, S.P.,Tegley, C.M.,Joseph, P.R.B.,Reynolds, C.H.,Sambashivan, S.
Uncompetitive, adduct-forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease.
Neuron, 110:3711-, 2022
Cited by
PubMed Abstract: Axon degeneration is an early pathological event in many neurological diseases. The identification of the nicotinamide adenine dinucleotide (NAD) hydrolase SARM1 as a central metabolic sensor and axon executioner presents an exciting opportunity to develop novel neuroprotective therapies that can prevent or halt the degenerative process, yet limited progress has been made on advancing efficacious inhibitors. We describe a class of NAD-dependent active-site SARM1 inhibitors that function by intercepting NAD hydrolysis and undergoing covalent conjugation with the reaction product adenosine diphosphate ribose (ADPR). The resulting small-molecule ADPR adducts are highly potent and confer compelling neuroprotection in preclinical models of neurological injury and disease, validating this mode of inhibition as a viable therapeutic strategy. Additionally, we show that the most potent inhibitor of CD38, a related NAD hydrolase, also functions by the same mechanism, further underscoring the broader applicability of this mechanism in developing therapies against this class of enzymes.
PubMed: 36087583
DOI: 10.1016/j.neuron.2022.08.017
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.09 Å)
構造検証レポート
Validation report summary of 8d0c
検証レポート(詳細版)ダウンロードをダウンロード

227561

件を2024-11-20に公開中

PDB statisticsPDBj update infoContact PDBjnumon